A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
On September 10, 2025, MEI Pharma, Inc. changed its name to Lite Strategy, Inc. and its ticker symbol to LITS. We are a pharmaceutical company that has been developing novel and differentiated cancer therapies. We built our pipeline by acquiring promising cancer agents and creating value in programs through clinical development, strategic partnerships and out-licensing or commercialization, as appropriate. Our approach to oncology drug development has been to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. Our drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3Kδ inhibitor, which is a pre-clinical candidate. In August 2025, as described below, we implemented a Litecoin Treasury Strategy with the net proceeds from the PIPE (as defined below).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 65M | 49M | 41M | 35M |
| Net Income | -40M | -16M | 18M | -32M | -54M | -41M |
| EPS | $-1.82 | $-2.39 | $2.67 | $-4.78 | $-9.99 | $-0.60 |
| Free Cash Flow | 0 | -21M | -50M | -53M | -49M | -33M |
| ROIC | -48.2% | -94.2% | 44.0% | -117.9% | - | - |
| Gross Margin | - | - | - | - | 100.0% | 96.0% |
| Debt/Equity | 0.00 | 0.08 | 0.25 | 3.91 | - | - |
| Dividends/Share | $0.00 | $0.00 | $0.33 | $0.00 | - | - |
| Operating Income | -39M | -17M | 15M | -37M | -75M | -60M |
| Operating Margin | 0.0% | - | 22.3% | -75.3% | -185.5% | -173.7% |
| ROE | -48.5% | -63.8% | 53.8% | -129.3% | - | - |
| Shares Outstanding | 36M | 36M | 36M | 7M | 5M | 69M |
Lite Strategy, Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 98.0%. At current prices, the estimated annualized return to fair value is +82.9%.
Lite Strategy, Inc. (LITS) has a 5-year average return on invested capital (ROIC) of -56.0%. This is below average and may indicate limited pricing power.
Lite Strategy, Inc. (LITS) has a market capitalization of $41M. It is classified as a small-cap stock.
Lite Strategy, Inc. (LITS) does not currently pay a regular dividend.
Lite Strategy, Inc. (LITS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Lite Strategy, Inc. (LITS) generated $-21 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Lite Strategy, Inc. (LITS) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
Lite Strategy, Inc. (LITS) reported earnings per share (EPS) of $-2.39 in its most recent fiscal year.
Lite Strategy, Inc. (LITS) has a return on equity (ROE) of -63.8%. A negative ROE may indicate losses or negative equity.
Lite Strategy, Inc. (LITS) has a 5-year average gross margin of 98.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for Lite Strategy, Inc. (LITS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lite Strategy, Inc. (LITS) has a book value per share of $0.47, based on its most recent annual SEC filing.